Dry Eye Syndrome
Investigational use for dry eye disease; mechanism via reduction of meibomian gland inflammation. Weak case-series evidence.
Resumen para el Paciente
- ¿Está esto autorizado por FDA para este uso?
- Not FDA-cleared for dry eye disease. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use for dry eye is investigational.
- ¿Qué evidencia existe?
- Tier C (investigational). One small pilot (Vora 2018, n=20) reported improvement in OSDI and Schirmer values after 2 sessions. There are no randomized controlled trials. Evidence-based interventions include artificial tears, cyclosporine ophthalmic, lifitegrast, punctal plugs, warm compresses, and meibomian-gland-directed treatments — all supported by RCTs and remain first-line.
- Riesgos principales
- Bleeding from bite sites for 6 to 24 hours after detachment (peri-orbital location)
- Bruising and tenderness near the temple and brow for 5 to 10 days
- Itching and irritation at bite sites near sensitive periocular skin
- Local skin infection or, rarely, Aeromonas infection
- Catastrophic harm if leech is mistakenly applied to the eyelid, conjunctiva, or orbit (NEVER do this)
- Allergic reaction to leech saliva (uncommon)
- Small permanent scars at bite sites
- Quién no debería considerar esto
- Patients on blood thinners (warfarin INR >2.0, DOACs, heparin)
- Patients with hemophilia or other bleeding disorders
- Patients with severe anemia (Hb <10 g/dL)
- Patients with recent ocular surgery (<3 months) or active eye infection
- Patients with active blepharitis with infection
- Patients considering this instead of an ophthalmology workup for severe or worsening dry eye
- Qué preguntar a su clínico
- Have I been evaluated by ophthalmology for underlying causes (Sjogren syndrome, meibomian dysfunction, neurotrophic dryness)?
- Have I completed adequate trials of artificial tears, cyclosporine, lifitegrast, and warm compresses?
- What evidence supports leech therapy for dry eye specifically?
- How will leeches be kept off the eyelid, conjunctiva, and orbit?
- What is the realistic chance of benefit, and for how long?
- What is the practitioner's experience and Aeromonas-prevention plan?
- What is the cost?
- Cuándo buscar atención urgente
- Sudden severe eye pain or vision change
- Spreading redness or pus near the eye (orbital cellulitis)
- Bleeding from a bite site lasting more than 24 to 48 hours
- Fever above 38.0 C / 100.4 F or chills
- Hives, throat tightness, or breathing difficulty
Qué NO significa esto
- This is not FDA-cleared for dry eye disease.
- A single 20-patient pilot is not evidence of efficacy beyond placebo in the general population.
- Mechanism rationale (meibomian anti-inflammation) does NOT establish clinical efficacy.
- Leech therapy is not a substitute for ophthalmologic evaluation or evidence-based topical therapy.
- Reported improvement on short-term symptom scores does not predict durable benefit.
Referencias cruzadas de seguridad
Clinical Profile
- Category
- ophthalmologic
- ICD-10
- H04.121, H04.122, H04.123, H04.129
- Safety tier
- medium
Evidence Summary
No controlled clinical trial or quantified case series of leech therapy for dry eye syndrome has been published; use is investigational and mechanistic only. The hypothesized mechanism involves reduction of meibomian gland inflammation via systemic anti-inflammatory effects of absorbed salivary peptides, but this has not been demonstrated on validated outcomes such as OSDI or Schirmer testing. If applied at all, leeches are placed on the temple or supraorbital ridge and NEVER on the eyelid. The evidence base is absent, so leech therapy cannot be recommended over standard interventions (artificial tears, cyclosporine, lifitegrast, punctal plugs) and should be reserved, if used, for research settings under ophthalmologist supervision.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Vora A et al. (2018), n=20
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Recent (<3 months) eye surgery
- Active conjunctivitis or blepharitis with infection
Related Conditions
Glaucoma (Adjunctive)
Investigational adjunctive use in primary open-angle glaucoma; weak case-series evidence. Not a substitute for IOP-lowering eye drops or surgery.
Thyroid Eye Disease (Investigational Periocular Adjunct)
Highly investigational periocular adjunct for stable thyroid eye disease; ocular risk is critical; teprotumumab and orbital decompression remain primary.